Does Rallies show Form 4 insider transactions for CNSP?

Yes. Rallies tracks CNSP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CNSP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CNSP. It does not provide personalized investment advice.

CNSP (CNS Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

CNS Pharmaceuticals, Inc. Common Stock (CNSP) is a publicly traded Healthcare sector company. As of May 21, 2026, CNSP trades at $4.98 with a market cap of $3.82M and a P/E ratio of -0.14. CNSP moved +10.88% today. Year to date, CNSP is -3.43%; over the trailing twelve months it is -67.05%. Its 52-week range spans $1.90 to $221.94. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces CNSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CNSP stock inside the company?

Recent CNSP insider activity includes Charles Faith L. bought 7.10K, Gumulka Jerzy bought 33.33K, Evans Carl Anthony bought 33.33K, Downs Christopher bought 66.67K, and Climaco John M bought 166.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CNSP Key Metrics

Key financial metrics for CNSP
Metric	Value
Price	$4.98
Market Cap	$3.82M
P/E Ratio	-0.14
EPS	$-35.75
Dividend Yield	0.00%
52-Week High	$221.94
52-Week Low	$1.90
Volume	243
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.85M
Gross Margin	0.00%

Recent CNSP Insider Trades

Charles Faith L. bought 7.10K (~$34.00K) on May 18, 2026.
Gumulka Jerzy bought 33.33K (~$10.00K) on Feb 1, 2024.
Evans Carl Anthony bought 33.33K (~$10.00K) on Feb 1, 2024.
Downs Christopher bought 66.67K (~$20.00K) on Feb 1, 2024.
Climaco John M bought 166.67K (~$50.00K) on Feb 1, 2024.

Latest CNSP News

CNS Pharmaceuticals Raises $22.5M, Launches Acquisition-Driven Strategy — May 14, 2026
CNS Pharmaceuticals Plans Out-Licensing of Berubicin, TPI 287 to Fund Neurology and Oncology Acquisitions — Mar 11, 2026
CNS Pharmaceuticals Appoints Lynne Kelley as CMO with 20-Year Phase 1-3 Leadership — Mar 2, 2026
CNS Pharmaceuticals Appoints CFO, CTO and CBO with 15–30 Years Experience — Feb 17, 2026

CNSP Analyst Consensus

1 analysts cover CNSP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about CNSP

Who is trading CNSP stock inside the company?: Recent CNSP insider activity includes Charles Faith L. bought 7.10K, Gumulka Jerzy bought 33.33K, Evans Carl Anthony bought 33.33K, Downs Christopher bought 66.67K, and Climaco John M bought 166.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CNSP?: Yes. Rallies tracks CNSP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CNSP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CNSP. It does not provide personalized investment advice.